NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Rein Therapeutics Inc. (RNTX) Stock Analysis

Rein Therapeutics Inc. (RNTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RNTX

$0.62

+$0.03 (+4.99%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RNTX with… →

RNTX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.61
Previous Close
$0.60
Day's Range
0.60–0.65
52-Week Range
0.54–2.18
Volume
265.75K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.36
Valuation
Market Cap
$53.90M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.68
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$49.87M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
86.27M
1-Year Return
−51.19%
Dividend and dates
Avg Volume
450.70K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RNTX closed at $0.62, −51.19% over 1 year.

Rein Therapeutics Inc. (RNTX) has a market capitalization of $53.90M.

In fiscal 2025, RNTX reported revenue of $0.00.

RNTX Stock Return by Calendar Year

Rein Therapeutics Inc. (RNTX) return since Jun 2017: what $10,000 became

1 year
$10,000 $4,881
−51.19%
5 years
$10,000 $309
−96.91%
Since Jun 2017
$10,000 $29
−99.71%

If you had invested $10,000 in Rein Therapeutics Inc. (RNTX) at the close on June 29, 2017, the earliest close on record here, it would have been worth $29 at the close on October 21, 2026: −99.71% in total, −46.62% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−46.14%
2025−49.57%
2024−24.57%
2023+28.65%
2022−78.95%
2021−45.87%
2020+81.50%
2019−31.79%
2018−92.03%
2017 (partial year)−2.41%

As of October 21, 2026.

RNTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$49.87M—
2024$0.00−$62.88M—
2023$0.00−$15.73M—
2022$0.00−$27.33M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$21.93M−$49.87M—
2024$0.00—−$28.11M−$62.88M—
2023$0.00—−$15.35M−$15.73M—
2022$0.00—−$27.65M−$27.33M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Rein Therapeutics Inc. (RNTX) is capitalised at $53.90M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 10.

RNTX last closed at $0.62 on October 21, 2026. That is +$0.03 (+4.99%) against the previous close. The 52-week range on file runs from $0.54 to $2.18. The latest close sits 15.7% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $49.87M. Trailing earnings per share are −1.68.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −51.19%. Across 5 years the annualized return works out at −50.10%. Beta against the wider market is reported at 1.36. Annualized volatility over the trailing 9 years is 111.83%.

Growth & Income

The record shows no dividend for RNTX.

The strongest complete calendar year on file is 2020 at +81.50%; the weakest is 2018 at −92.03%. Of the 8 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is −46.14% year to date.

Peer Comparison

Rein Therapeutics Inc. (RNTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rein Therapeutics Inc. RNTX $53.90M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Rein Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Rein Therapeutics Inc.

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.

Visit website →